高级检索
当前位置: 首页 > 详情页

Changes in the prevalence of polycystic ovary syndrome in China over the past decade

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ SSCI

单位: [1]Peking Univ Third Hosp, Ctr Reprod Med, Dept Obstet & Gynecol, Beijing 100191, Peoples R China [2]Natl Clin Res Ctr Obstet & Gynecol, Beijing 100191, Peoples R China [3]Peking Univ, Key Lab Assisted Reprod, Minist Educ, Beijing 100191, Peoples R China [4]Beijing Key Lab Reprod Endocrinol & Assisted Repro, Beijing 100191, Peoples R China [5]Guangzhou Med Univ, Guangzhou Inst Pediat, Guangzhou Women & Childrens Med Ctr, Guangzhou 510623, Peoples R China [6]Guangzhou Med Univer, Guangzhou Women & Childrens Med Ctr, Dept Obstet & Gynecol, Guangzhou 510623, Peoples R China [7]Peking Univ, Dept Reprod Med, Shenzhen Hosp, Shenzhen 518036, Peoples R China [8]Shanghai Jiao Tong Univ, Sch Med, Dept Pathophysiol, Key Lab Cell Differentiat, Shanghai 200240, Peoples R China [9]First People s Hosp Yunnan Prov, Dept Reprod Med, Kunming 650021, Peoples R China [10]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Reprod Med Ctr, Wuhan 430030, Peoples R China [11]Affiliated Hosp Shanxi Med Univ, Children Hosp Shanxi s, Reprod Med Ctr, Women Hlth Ctr Shanxi, Taiyuan 030000, Peoples R China [12]Henan Prov People s Hosp, Reprod Med Ctr, Zhengzhou 450003, Peoples R China [13]Fujian Med Univ, Fujian Matern & Child Hlth Hosp, Coll Clin Med Obstet & Gynecol & Pediat, Reprod Med Ctr, Fuzhou 350001, Peoples R China [14]Shengjing Hosp China Med Univ, Ctr Reprod Med, Dept Obstet & Gynecol, Shenyang 110022, Peoples R China [15]Hebei Med Univ, Dept Reprod Med, Hosp 2, Shijiazhuang 050000, Peoples R China [16]West China Second Univ Hosp Sichuan Univ, Div Reprod Med Ctr, Chengdu 610041, Peoples R China [17]Univ Adelaide, Robinson Res Inst, Discipline Obstet Gynecol, Adelaide, SA 5005, Australia
出处:

关键词: Polycystic ovary syndrome Prevalence Trend Ultrasound

摘要:
Background Polycystic ovary syndrome (PCOS) has become a major international public health concern. However, because of controversy about the diagnostic criteria and patient selection, estimates of its absolute prevalence and change with time vary greatly.Methods We conducted two consecutive nationwide epidemiological surveys of the prevalence of PCOS in representative samples of reproductive-aged women in China in 2010 and 2020. Face-to-face interviews were performed by trained interviewers in each survey. All participants completed a questionnaire and underwent a physical examination, blood sampling, and transvaginal pelvic ultrasound. We assessed hyperandrogenism (H), chronic anovulation (O), and polycystic ovaries (P) to classify the presence of PCOS using the Rotterdam criteria. The prevalence of PCOS among reproductive-aged women was estimated after consideration of differential probabilities of selection and population distribution. We conducted a logistic regression analysis by using the probability of PCOS as a function of the survey year to acquire the trend information across the years.Findings 28,739 respondents completed the survey, including 15,924 in the previously published 2010 survey and 12,815 in the new 2020 survey. In 2020, 826 participants could be diagnosed as having PCOS, with a weighted prevalence of 7.8% (95%CI: 7.0%, 9.0%) among women aged 20-49 years, leading to an estimate of 24.0 million women of reproductive age affected by this condition in China as a whole. The estimated prevalence in 2020 was higher than that of a decade ago despite identical research methods suggesting a two-thirds increase over the study period. Women with PCOS in 2020 also appeared to have a more severe phenotype overall than those of a decade ago, possibly reflecting a significantly higher prevalence of obesity, hyperandrogenism, and infertility.Interpretation The prevalence of PCOS in Chinese women has increased significantly over the past 10 years. PCOS is a significant public health problem in women of reproductive age in China and national policy and guidelines should be re-examined in the light of the current data.Funding National Key R&D Program of China and the National Natural Science Foundation of China.Copyright (c) 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 卫生保健与服务 1 区 公共卫生、环境卫生与职业卫生
JCR分区:
出版当年[2020]版:
最新[2023]版:
Q1 HEALTH CARE SCIENCES & SERVICES Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者单位: [1]Peking Univ Third Hosp, Ctr Reprod Med, Dept Obstet & Gynecol, Beijing 100191, Peoples R China [2]Natl Clin Res Ctr Obstet & Gynecol, Beijing 100191, Peoples R China [3]Peking Univ, Key Lab Assisted Reprod, Minist Educ, Beijing 100191, Peoples R China [4]Beijing Key Lab Reprod Endocrinol & Assisted Repro, Beijing 100191, Peoples R China
通讯作者:
通讯机构: [1]Peking Univ Third Hosp, Ctr Reprod Med, Dept Obstet & Gynecol, Beijing 100191, Peoples R China [2]Natl Clin Res Ctr Obstet & Gynecol, Beijing 100191, Peoples R China [3]Peking Univ, Key Lab Assisted Reprod, Minist Educ, Beijing 100191, Peoples R China [4]Beijing Key Lab Reprod Endocrinol & Assisted Repro, Beijing 100191, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:589 今日访问量:0 总访问量:441 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)